Open in interactive viewer → charts, metric popovers & call review

SeaStar's Fourth Enrollment Sled: NEUTRALIZE-AKI Slips to Mid-2027 as Cash Counts Down

QUELIMMUNE revenue rises 247% off a $630K base and a seventh Breakthrough Device Designation lands for sepsis — but the pivotal trial's finish line moved again, and the filing math now points to a 2029 approval on 2.3 quarters of runway.
ICU · Earnings Call · 2026-11-11

The slip that matters

SeaStar Medical's stock is down 62% over the last 90 trading days, from a July 8 peak of $5.08 to roughly $1.92 — the whole history is a 99.9% drawdown from the 2022 highs. The third-quarter call explains the drift, and it is not the revenue line. NEUTRALIZE-AKI, the pivotal adult trial, has enrolled 251 of 339 patients, about 75% of the way there. But the finish line moved:

As a result, we are adjusting our guidance for completion of enrollment in the trial. Based on our current enrollment rate, we would anticipate completing the trial by midyear of 2027. ... We are clearly disappointed to extend the time line for completion of enrollment.

Eric Schlorff, Chief Executive Officer · 2026-11-11
The honesty is refreshing; the pattern is not. On the November 2025 call, the Chief Medical Officer was explicit: “with the additional eight sites, we are going to be able to meet the goal of 339 by December 2026.” — Kevin Chung, Chief Medical Officer · 2025-11-13 By August 2026 the language had softened to a year-end 2026 / first-quarter 2027 window, alongside an admission that enrollment was running “somewhere around 8 to 10 to 12 patients in each of those months. And that is relatively slower than what I would like.” — Colonel Kevin Chung FACP · 2026-08-12 Now the target is mid-2027 — the third distinct public target for the same completion of enrollment milestone. The downstream arithmetic is brutal for a company this size. Management says the final PMA module lands about nine months after last-patient-in, then a 180-day FDA clock. Analyst Anthony Vendetti walked the timeline out loud and management did not dispute it: file around the first quarter of 2028, approval around 2029. That is a long bridge for a company with a $5.4 million market cap.

A real commercial signal, wrapped in a very small base

What is genuinely improving is QUELIMMUNE. Net revenue reached roughly $635,000 in the quarter, up 247% year over year, and nine-month revenue of $1.7 million means management now expects to “exceed our guidance of $2 million in QUELIMMUNE revenue for the year.” — Tim Varacek, Senior Vice President · 2026-11-11 Gross margin held above 90%. Twenty of the top 50 pediatric centers are customers, up from 17 in May 2026 and three or four a year earlier — a rate of new-site addition that has been commendably steady. But the sequential line is flat, and management was asked about it directly. Tim Varacek's answer deflected rather than explained: “in terms of the flatness of the revenue versus Q2, what I would compare to is where we were Q3 last year.” — Tim Varacek, Senior Vice President · 2026-11-11 Fair for a year-over-year business, less fair for an incidence-driven model where the incremental customer adds should eventually compound. Two operational unlocks were flagged as adoption accelerants: the FDA confirming the SAVE Registry requirement has been met, and new CMS ICD-10-PCS codes that let hospitals bill for the procedure. Those are real friction removers — worth watching in the fourth quarter, when the company will not guide to a number.

The clinical evidence is the best thing here — and still not an approval

Kevin Chung's late-breaking SAVE registry presentation at ASN Kidney Week is the strongest asset in the story: 50 treated pediatric patients, no device-related adverse events, and a 65% 90-day survival rate versus 47% in a clinically aligned Kids' Inpatient Database cohort, significant at p=0.043, with roughly a third of patients on ECMO. In a population where fewer than half historically survive, that is a meaningful signal from a registry, not a randomized trial. The bigger optionality is sepsis. The FDA granted a seventh Breakthrough Device Designation for hyperinflammation in adult patients with sepsis or a septic condition, and the existing NEUTRALIZE-AKI protocol carries a prespecified sepsis analysis. Eric Schlorff expects that subpopulation to be well over 70% of enrollees — meaning the same trial may generate the evidence for two indications. Here the history counsels caution. Breakthrough designations have been a recurring headline for this company since at least May 2025, when a prior call discussed two additional designations and five extra indications; the Critical Care keyword has topped the company's own keyword ranking for multiple quarters while approvals have not followed. A designation is a scheduling privilege, not a revenue event. Kevi

The cash equation is the real quarter

The financials, not the science, set the clock. Operating expenses ran $5.2 million against $635,000 of revenue; net loss was $4.5 million, or $1.03 per share. Cash at September 30 was about $4 million, plus $3.3 million of gross warrant proceeds collected in October — roughly $7.3 million against a quarterly burn near $4.5 million. That is a little over two quarters of runway, and effective net cash has fallen from a 2025 peak above $14 million. The spending is not waste — R&D is up 143% year over year, which is what a company mid-pivot-to-pivotal should show. But it means financing is the next scheduled event, and the October warrant exercise is the tell: the capital structure, not the trial, will decide the equity outcome.

What changed

Three things, in order of importance. First, the NEUTRALIZE-AKI timeline slipped again and the approval date now sits at 2029, which pushes any adult-AKI revenue past the current cash position by a wide margin. Second, QUELIMMUNE is quietly becoming a real, if ultra-narrow, product — the >$2 million guidance beat, declining registry friction, and billable procedure codes are all genuine progress on the only revenue line the company has. Third, the sepsis designation is the most interesting free option in the story, precisely because it may ride on data already being collected. What has not changed is the structure of the bet: a $5 million market cap, a therapy with compelling registry evidence, and a bridge that must be financed before the evidence converts. The call was more candid than most about the delay. The tape has already voted on what the delay costs.